Valuation: Gain Therapeutics, Inc.

Market Cap 71.66M 62.65M 57.79M 53.13M 101M 6.9B 102M 690M 271M 3.37B 269M 263M 11.62B P/E 2026 *
-3.01x
P/E 2027 * -2.26x
Enterprise Value 71.66M 62.65M 57.79M 53.13M 101M 6.9B 102M 690M 271M 3.37B 269M 263M 11.62B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.71%
Yield 2026 *
-
Yield 2027 * -
1 day-0.60%
1 week-6.15%
Current month-17.24%
1 month-4.00%
3 months-21.50%
6 months-10.64%
Current year-47.83%
1 week 1.59
Extreme 1.59
1.86
1 month 1.59
Extreme 1.59
2.24
Current year 1.53
Extreme 1.53
3.29
1 year 1.41
Extreme 1.41
4.34
3 years 0.89
Extreme 0.89
5.33
5 years 0.89
Extreme 0.89
9.75
10 years 0.89
Extreme 0.89
17.93
Manager TitleAgeSince
Chief Executive Officer 52 2024-06-24
Director of Finance/CFO 37 2025-01-05
Chief Tech/Sci/R&D Officer - 2024-03-24
Director TitleAgeSince
Chairman 69 2016-12-31
Director/Board Member 63 2019-04-30
Director/Board Member 58 2020-12-31
Date Insider Type Main position Quantity % Market Cap.
03-23Free

Chief Executive Officer

200,000 0.5200%
03-23Free

Chief Financial Officer

50,000 0.1300%
25-06-23Free

Director

15,000 0.0507%
Change 5-day change 1-year change 3-year change Capi.($)
-0.60%-6.15%-1.18%-62.16% 71.66M
-1.34%-1.61%+0.60%+5.91% 50.35B
-1.19%-2.81%+387.81%+591.82% 39.21B
+1.51%+1.48%+31.16%-6.46% 34.52B
+1.11%+3.11%+15.41%+58.54% 34.6B
+1.68%-0.62%+3.30%+27.34% 27.05B
-0.92%-3.11% - - 16.68B
+0.46%-0.52%+69.24%+117.60% 15.11B
-0.38%+0.32%+14.16%+17.50% 13.85B
+0.28%+3.99%+18.20%-30.12% 13.18B
Average -0.12%+0.23%+59.85%+80.00% 24.46B
Weighted average by Cap. -0.14%+0.82%+80.79%+121.36%

Financials

2026 *2027 *
Net sales - -
Net income -24.41M -21.34M -19.68M -18.09M -34.29M -2.35B -34.87M -235M -92.21M -1.15B -91.65M -89.65M -3.96B -36.06M -31.53M -29.08M -26.73M -50.65M -3.47B -51.52M -347M -136M -1.7B -135M -132M -5.85B
Net Debt - -
Logo Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
Employees
21
Date Price Change Volume
26-07-15 US$1.680 0.00% 995,530
26-07-14 US$1.680 -4.55% 1,468,565
26-07-13 US$1.760 -2.22% 997,398
26-07-10 US$1.800 -1.10% 610,322
26-07-09 US$1.820 +1.68% 589,393
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.680USD
Average target price
7.200USD
Spread / Average Target
+328.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GANX Stock